Mitapivat
295 interactions 80 cited referencesMitapivat is used to treat hemolytic anemia (a blood disorder that occurs when red blood cells are destroyed faster than they can be made in the body) in people with pyruvate kinase deficiency. Mitapivat is in a class of medications called pyruvate kinase activators. It works by increasing pyruvate kinase available to… Read the full Mitapivat drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Mitapivat Naloxegol Movantik Reduced CYP3A substrate exposure Details Mitapivat Nefazodone Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Nelfinavir Viracept Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Nerandomilast Reduced nerandomilast exposure and reduced efficacy of nerandomilast Details Mitapivat Neratinib Nerlynx Reduced CYP3A substrate exposure Details Mitapivat Netupitant Increased mitapivat exposure Details Mitapivat Nifedipine Adalat® Reduced NIFEdipine exposure Details Mitapivat Nilotinib Increased mitapivat exposure and reduced CYP3A4 substrate exposure Details Mitapivat Nirmatrelvir Reduced CYP3A substrate exposure Details Mitapivat Nirogacestat Ogsiveo Increased mitapivat exposure and reduced CYP3A4 substrate exposure Details Mitapivat Nisoldipine Sular Reduced CYP3A substrate exposure Details Mitapivat Nomegestrol Reduced hormonal contraceptive exposure Details Mitapivat Norelgestromin Reduced hormonal contraceptive exposure Details Mitapivat Norethindrone Aygestin Reduced hormonal contraceptive exposure Details Mitapivat Norgestimate Reduced hormonal contraceptive exposure Details Mitapivat Norgestrel Reduced hormonal contraceptive exposure Details Mitapivat Olaparib Lynparza Reduced CYP3A substrate exposure Details Mitapivat Oliceridine Olinvyk Reduced oliceridine exposure and reduced efficacy of oliceridine Details Mitapivat Omaveloxolone Skyclarys Reduced omaveloxolone exposure, reduced efficacy of omaveloxolone, reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A... Details Mitapivat Orforglipron Foundayo Reduced orforglipron exposure and reduced efficacy of orforglipron Details Mitapivat Oxycodone Oxaydo Reduced CYP3A substrate exposure Details Mitapivat Paclitaxel Abraxane Reduced PACLitaxel exposure Details Mitapivat Pacritinib Vonjo® Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Paltusotine Palsonify Reduced paltusotine exposure and reduced efficacy of paltusotine Details Mitapivat Paritaprevir Increased mitapivat exposure, an increased risk of mitapivat-related adverse reactions and reduced CYP3A substrate exposure Details Mitapivat Pazopanib Votrient Reduced CYP3A substrate exposure Details Mitapivat Pexidartinib Turalio Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Phenobarbital Fidoquel Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Phenytoin Dilantin Reduced phenytoin or fosphenytoin (prodrug of phenytoin) exposure, reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Pimavanserin Nuplazid Reduced CYP3A substrate exposure Details Mitapivat Pimozide Reduced CYP3A substrate exposure Details Mitapivat Posaconazole Noxafil Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Primidone Mysoline Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Quetiapine Seroquel Reduced CYP3A substrate exposure Details Mitapivat Quinidine Cardioquin® Reduced CYP3A substrate exposure Details Mitapivat Quinine Reduced CYP3A substrate exposure Details Mitapivat Quizartinib Vanflyta Reduced quizartinib exposure and reduced efficacy of quizartinib Details Mitapivat Relacorilant Lifyorli Increased CYP3A4 substrate exposure, increased risk of CYP3A4 substrate-related adverse reactions, reduced relacorilant exposure a... Details Mitapivat Remibrutinib Rhapsido Reduced remibrutinib exposure and reduced efficacy of remibrutinib Details Mitapivat Repotrectinib Augtyro Reduced repotrectinib exposure, reduced mitapivat exposure and reduced efficacy of mitapivat DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist